Needham analyst David Saxon downgraded Dentsply Sirona (XRAY) to Hold from Buy without a price target With a debate around whether the dental market’s long-term growth profile has shifted lower and recent indicators pointing to weakening U.S. consumer sentiment, Needham does not expect dental market growth to improve in the near-term, the analyst tells investors in a research note. The firm says that with Dentsply and ZimVie both seeing below-market growth and no meaningful upside catalyst to drive near-term multiple expansion, it no longer believes the stocks can outperform relative to its broader coverage.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XRAY:
- Utah fluoride ban could be marginal tailwind to dental demand, says BofA
- Dentsply Sirona director buys $250K in common stock
- Hold Rating Maintained for DENTSPLY SIRONA Amid Market Challenges and Strategic Uncertainty
- DENTSPLY SIRONA’s Mixed Earnings Call Insights
- Dentsply Sirona price target lowered to $20 from $24 at Barrington
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue